why choose us

Clinical Trials Search

Showing 14,930 of 132,963 result(s)
Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

Status: Completed

Condition: Coronary Allograft Vasculopathy (CAV)

Interventions: CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these curren

Date: 2023-02-21

Phase I;IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Status: Completed

Condition: Ovarian Cancer

Interventions: IV Antibody-drug conjugate

Date: 2023-02-21

A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment

Status: Completed

Condition: Female Dyspareunia

Interventions: Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0
Hz, 0.06-0.10
mJ;mm2 (Intensity of 6-8), 8 to 12 minutes

Date: 2023-02-21

Identify the Optimal TMS Target to Modulate Reward Activity

Status: Completed

Condition: Nicotine Use Disorder

Interventions: The active group will receive 10hz TMS stimulation.
Participants in the active stimulation group will receive10-Hz TMS to left DLPFC.
The LD

Date: 2023-02-21

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Status: Completed

Condition: Hepatic Impairment

Interventions: Participants receive mitiperstat orally.

Date: 2023-02-21

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Status: Completed

Condition: Heart Failure

Interventions: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo;placebo, bendro

Date: 2023-02-21

Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia

Status: NOT_YET_RECRUITING

Condition: Developmental Prosopagnosia

Interventions: Computer-based training using faces targeting face memory

Date: 2023-02-21

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Status: Completed

Condition: Non-Small Cell Lung Cancer

Interventions: Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.

Date: 2023-02-21

Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor

Status: Completed

Condition: Labor Long

Interventions: Low dose oxytocin

Date: 2023-02-21

Digital vs. Speculum Exams for PPROM

Status: Completed

Condition: PPROM

Interventions: Same as arm

Date: 2023-02-21